Review anchor
Dihydroorotate dehydrogenase (quinone), mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Dihydroorotate dehydrogenase (quinone), mitochondrial
CHEMBL1966
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dihydroorotate dehydrogenase (quinone), mitochondrial as ChEMBL target CHEMBL1966, mapped to UniProt Q02127. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1966
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q02127
Dihydroorotate dehydrogenase (quinone), mitochondrial
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Dihydroorotate dehydrogenase (quinone), mitochondrial matters
Dihydroorotate dehydrogenase (quinone), mitochondrial is reviewed as Dihydroorotate dehydrogenase (quinone), mitochondrial (UniProt Q02127); Dihydroorotate dehydrogenase (quinone), mitochondrial shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 2908 compounds, and 293 assays, with lead potency reaching pChEMBL 9.9.
Protein context
Dihydroorotate dehydrogenase (quinone), mitochondrial
Dihydroorotate dehydrogenase (quinone), mitochondrial Sequence length is 395 aa.
Review this target as Dihydroorotate dehydrogenase (quinone), mitochondrial, mapped to UniProt Q02127. Sequence length is 395 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q02127
Protein
Disease context
multiple sclerosis
Dihydroorotate dehydrogenase (quinone), mitochondrial shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TERIFLUNOMIDE, VIDOFLUDIMUS.
Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include TERIFLUNOMIDE, VIDOFLUDIMUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 2908 compounds, and 293 assays for this target. The dominant activity type is IC50. CHEMBL4744558 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL4744558 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 9.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Dihydroorotate dehydrogenase (quinone), mitochondrial matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q02127, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why multiple sclerosis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2908
Total Compounds
293
Total Assays
5
Approved Drugs
IC50: 3211.0, KI: 265.0, EC50: 26.0, KD: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4744558
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL5077700
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL5405642
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5085549
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5075013
|
9.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TERIFLUNOMIDE
CHEMBL973
|
2012 |
|
|
LEFLUNOMIDE
CHEMBL960
|
1998 |
Source Header